In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects

Pomalidomide is an immunomodulatory drug, and the dosage of 4 mg per day taken orally on days 1‐21 of repeated 28‐day cycles has been approved in the European Union and the United States to treat patients with relapsed/refractory multiple myeloma. In vitro data showed that pomalidomide is a substrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Liu, Liangang, Wang, Xiaomin, Zhang, Chengyue, Reyes, Josephine, Hoffmann, Matthew, Palmisano, Maria, Zhou, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175223/
https://www.ncbi.nlm.nih.gov/pubmed/29762875
http://dx.doi.org/10.1002/jcph.1145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175223/
https://www.ncbi.nlm.nih.gov/pubmed/29762875
http://dx.doi.org/10.1002/jcph.1145

Ejemplares similares